1.	Phase III Randomized Study of Eflornithine in Patients with Low Grade, Superficial Transitional Cell Carcinoma of the Bladder Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: ILEX-DFMO341, N01-CN-25434-01, UCLA-9812049, UF-453-1998, WCCC-CO-98803, NCI-G99-1509, NCT00003814
2.	Phase III Randomized Comparison of Radiotherapy vs Combination Chemotherapy with DFMO/MEGAG vs No Postoperative Therapy in Patients with Non-Enhancing Moderately and Mildly Anaplastic Gliomas of the Brain (Summary Last Modified 02/88) Phase: Phase III Type: Treatment Status: Completed Age: 5 to 45 Sponsor: NCI Protocol IDs: NCOG-6G871, BTRC-8625, MDA-DM-88056, NCI-T86-0226D, T86-0226
3.	Phase III Trial of Accelerated Hyperfractionation with or without DFMO vs Single Fraction Radiotherapy with or without DFMO in Patients with Newly Diagnosed Glioblastoma Multiforme (Summary Last Modified 02/92) Phase: Phase III Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: BTRC-6G901, NCI-T91-0047O, T91-0047
4.	Phase III Randomized Trial of Procarbazine, Lomustine, and Vincristine (PCV) With or Without Eflornithine in Patients with Malignant Gliomas Previously Treated With Radiotherapy (Summary Last Modified 06/1999) Phase: Phase III Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-DM-92035, NCI-T92-0114C, T92-0114
5.	Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps Phase: Phase III Type: Prevention Status: Completed Age: 40 to 80 Sponsor: NCI, Other Protocol IDs: CDR0000429552, 2002-2261, UCIRVINE-UCI-2002-2261, NCT00118365
6.	Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Phase: Phase III Type: Prevention Status: Closed Age: 21 and over Sponsor: NCI, Other Protocol IDs: CDR0000067928, WCCC-CO-9737, NCI-P00-0155, NCT00005884
7.	Phase I/II Chemoprevention Study of Eflornithine (DFMO) in Patients At Risk for Colorectal Carcinoma (Summary Last Modified 02/98) Phase: Phase II, Phase I Type: Prevention Status: Closed Age: Over 18 Sponsor: NCI Protocol IDs: WCCC-CO-9221, NCI-P97-0096
8.	Phase I/II Chemotherapy with DFMO/MGBG in Patients with Adenocarcinoma of the Prostate Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-8525A, NCI-T85-0043D, T85-0043
9.	Phase II Chemoprevention Study of Difluoromethylornithine (DFMO) in Patients With Superficial Bladder Cancer Phase: Phase II Type: Prevention, Screening Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: WCCC-CO-9285, NCI-G97-1213
10.	Phase II Study of DiFluoroMethylOrnithine (DFMO) in Breast Dysplasia with Biomarker Abnormalities (Summary Last Modified 05/1999) Phase: Phase II Type: Prevention Status: Closed Age: 30-55 with exceptions Sponsor: NCI Protocol IDs: KUMC-HSC-6916-96, NCI-P97-0080
11.	Phase II Randomized, Double Blind, Placebo-Controlled Study of Eflornithine (DFMO) in Women with Breast Neoplasia (Summary Last Modified 03/98) Phase: Phase II Type: Prevention Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: UAB-9509, NCI-P97-0082
12.	Phase IIB Chemoprevention Study of Eflornithine (DFMO) in Patients with Intestinal-type Barrett's Esophagus (Summary Last Modified 07/2001) Phase: Phase II Type: Prevention Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: CCUM-9555, NCI-P97-0094, NCT00003076
13.	Phase II Randomized Study of Eflornithine versus Placebo for the Treatment of Leukoplakic Dysplasia (Summary Last Modified 12/1999) Phase: Phase II Type: Prevention Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: FCCC-94021, NCI-P97-0095
14.	Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ID92-026, P30CA016672, MDA-ID-92026, NCI-P00-0149, CDR0000067921, NCT00006079
15.	Phase IIB Randomized Chemoprevention Study of Eflornithine (DFMO) in Patients at High Genetic Risk For Prostate Cancer Phase: Phase II Type: Prevention Status: Closed Age: 35 to 70 Sponsor: NCI Protocol IDs: UCIRVINE-97-18, UCIRVINE-U01-CA-81886-01, NCI-P00-0164, NCT00006101
16.	Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis. Phase: Phase II Type: Prevention Status: Closed Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: ID00-109, P30CA016672, MDA-ID-00109, NCI-P02-0219, CDR0000069278, N01-CN-95040, NCT00033371
17.	Phase II Pilot Immunotherapy with Interferon and Chemotherapy with DFMO in Patients with Kaposi's Sarcoma and the Acquired Immune Deficiency Syndrome Phase: Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: NCI-84-C-179, NCI-T84-0477N, T84-0477
18.	Phase II Sequential Chemotherapy with DFMO Followed by MeGAG for Refractory Lymphoma or CLL Phase: Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: RPMI-PPC-764, NCI-T83-0886D
19.	Phase II Study of DFMO in Patients with Recurrent Malignant Gliomas (Summary Last Modified 07/91) Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-DM-88130, NCI-T88-0236H, T88-0236
20.	Phase II Study of Recombinant Interferon Alpha-2a/Eflornithine in Patients with Recurrent Gliomas (Summary Last Modified 11/90) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-867202, NCI-T89-0006C, T89-0006
21.	Phase II Pilot Study of DFMO Following Transurethral Resection of Superficial and Superficially Invasive Transitional Cell Carcinoma of the Urinary Bladder Phase: Phase II Type: Prevention Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-895151, EST-C-0490, MAYO-895151, I89-0001, NCI-P91-0008
22.	Phase IIb Cancer Prevention Trial of the Effect of the Polyamine Synthesis Inhibitor DFMO on Colon Mucosa (Summary Last Modified 09/95) Phase: Phase II Type: Prevention Status: Closed Age: 40 to 80 Sponsor: Other Protocol IDs: UCI-DFMO/COLON, NCI-P92-0007
23.	Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000353198, UAB-9921, UAB-F990728039, NCT00086736
24.	Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients Phase: Phase II Type: Prevention Status: Completed Age: 21 and over Sponsor: Other Protocol IDs: 2001-414, CO00318, NCT00204789
25.	Eflornithine Plus Sulindac in Preventing Colorectal Cancer in Patients With Benign Colorectal Polyps Phase: Phase II Type: Prevention Status: Completed Age: 40 to 80 Sponsor: NCI, Other Protocol IDs: CDR0000067922, 1997-96, NCI-P00-0150, UCIRVINE-97-05, NCT00005882